Noninvasive Diagnostic Panel for Liver Fibrosis

The test is based on three extracellular matrix remodeling proteins utilizing a new algorithm and unique index, thereby providing doctors with more clinically useful information. FibroSpect II is the product of Prometheus Laboratories, Inc. (San Diego, CA, USA), a specialty pharmaceutical company.

"In chronic hepatitis C infection, liver biopsy has been the favored approach to evaluate the extent of liver fibrosis and help guide treatment decisions; however, it is expensive, associated with possible complications, and limited by sampling error and observer variability,” said Dr. F. Fred Poordad, associate director, hepatology and liver transplants at Cedars Sinai Medical Center (Los Angeles, CA, USA). "Noninvasive methods to aid in assessing liver disease severity, such as FibroSpect II, provide additional diagnostic options.”





Related Links:
Promethues Labs